CliffBio
small molecule

VELETRI

EPOPROSTENOL SODIUM

Loss of exclusivityMarch 2027latest FDA-listed patent expiry
CompanyActelion →View the full company profile on CliffBio

Drug detail

Brand nameVELETRI
Active ingredientEPOPROSTENOL SODIUM
StrengthEQ 1.5MG BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJune 2008
Marketing statusRX

Listed patents

PatentExpiresType
8318802March 2027product
8598227February 2027—

More from Actelion

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VELETRI patent cliff — loss of exclusivity March 2027 | CliffBio